Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (NCT03727061), a na phase 1 study. The primary outcome is Frequency of Adverse Events Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

2. Clinical Question

The clinical question is principally about treatment safety and feasibility, rather than a comparative estimate of benefit. Interstitial photodynamic therapy uses a light-sensitive drug activated by laser light delivered through fibers placed into the tumor, according to the study summary. The record also lists nivolumab and a quality-of-life assessment among interventions, but it does not explain their relationship to the described arm or the primary endpoint. The intended chemotherapy comparison is likewise not resolved by the arm information. Consequently, the registry record does not define a clear contrast between treatment strategies. Any interpretation should remain limited to the enrolled group and the safety information posted, rather than treating the study as a test of whether the intervention is better than another treatment.

3. Trial Design

This is a phase I, single-group study registered as NCT03727061. Allocation is listed as not applicable, and masking is listed as none. The record reports enrollment of 5 and identifies locally advanced and recurrent head and neck carcinoma as the conditions of interest. It lists Roswell Park Cancer Institute as the sponsor. The recorded study start is 2019-07-10, the primary completion date is 2024-10-22, and the current status is terminated. The reason for termination is not reported in the registry record.

The described arm combines porfimer sodium with interstitial photodynamic therapy. The arm description says porfimer sodium is administered intravenously over 3-5 minutes and that the procedure takes place approximately 48 hours later. While the study title mentions treatment with or without standard-of-care chemotherapy, the arm description does not spell out a chemotherapy comparison. Nivolumab appears in the intervention list, but its use in the described arm is not explained. The registry record therefore leaves uncertainty about how all listed interventions relate to the treatment actually received.

The design information does not describe a randomized or masked comparison. With a single group, observations can describe events occurring among treated participants, but cannot by themselves separate treatment-associated effects from events related to the underlying cancer, other care, or chance. A concurrent comparator is not reported. The registry record also does not report a protocol rationale for the enrollment, a sample-size justification, interim analyses, or the statistical plan. The phase I designation and the stated safety aim establish the general context, but do not fill in those missing design details.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All treated and eligible patients

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All treated and eligible patients

6. Primary Endpoint

The registry lists the primary outcome as Frequency of Adverse Events Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, measured over Up to 30 days.

The primary endpoint is the frequency of adverse events under the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, with a timeframe of up to 30 days. It is expressed as a count of participants. The endpoint description says toxicities are to be tabulated according to the maximum grade of any adverse event experienced by a patient across dose levels and cycles. The primary population is described as all treated and eligible patients, while the toxicity description says anyone who receives any study treatment is evaluable for toxicity.

Safety endpoints are used in early-phase studies to characterize the kinds and severity of events observed during treatment and the period specified for follow-up. Grading provides a structured way to distinguish event severity; considering each patient's maximum grade can summarize the most severe event recorded for that patient, rather than treating every event as a separate participant. These are general features of toxicity reporting, not additional findings about this study.

The posted information supports a limited description of event counts. It does not provide, in the registry record for this analysis, a distribution of toxicity counts by maximum grade, dose level, or cycle, nor does it identify a formal comparison. The endpoint is not an efficacy measure, and its observed frequency does not establish that an event was caused by treatment. The registry record does not report a separate primary efficacy endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the primary outcome as a binary participant-level count: participants are classified according to whether an event was recorded, and the result is expressed as a count. This is distinct from counting the total number of event episodes. A participant who experiences more than one event may still contribute as a participant with an event, depending on the endpoint definition. The endpoint text additionally specifies tabulation by the maximum adverse-event grade experienced by a patient. These are general explanations of how participant-level toxicity summaries are read; the record does not provide all details of how each event was coded.

What does a participant count tell the reader?

A count records how many participants in the at-risk group had the specified event. The denominator matters because a count alone does not show the size of the group under observation. The posted results therefore identify both participants affected and participants at risk. Such a summary is descriptive: it reports what was recorded in this group. It does not, without an appropriate comparison and analysis, estimate the difference attributable to treatment.

Binary outcomes are often presented with an uncertainty interval to show how much the observed frequency could vary under repeated sampling. A confidence interval is a range produced by a statistical procedure with stated coverage properties; it is not a guarantee that the true value lies within the interval. This is general statistical context. The registry information summarized for this analysis does not report an interval for the primary endpoint, so no interval or precision estimate should be imputed. With a small enrolled group, intervals would generally be important to communicate uncertainty rather than treating the observed count as a stable estimate.

Why does the single-group design matter?

A single-group design can document events observed during treatment and can be useful for describing early safety experience. It does not supply a concurrent untreated or alternative-treatment estimate. Without that contrast, observed events may reflect treatment, the disease, other interventions, or factors not described in the registry. This limitation is not removed by a significance test; a statistical test cannot create a comparison that the design did not include.

The record lists no allocation and no masking. These entries are consistent with the stated single-group model, but the registry record does not provide additional details about participant selection, event adjudication, or assessment procedures. The title's reference to treatment with or without standard-of-care chemotherapy does not substitute for an arm definition or a stated analysis comparing those strategies. The role of nivolumab, also listed as an intervention, is not explained in the arm description.

How should the analysis plan be understood?

The registry reports 0 analyses. That means the record does not supply a formal analysis result in the entry; it does not demonstrate that no analyses were conducted outside the registry. The statistical plan, including the planned handling of missing data, multiplicity, and covariates, is not reported in the registry record. No adjustment method or inferential procedure should therefore be attributed to the trial.

The sample-size assumptions describe planning illustrations computed from an observed effect, not the trial's own design. Those illustrations use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is described as a stated fraction of the observed effect. These are assumptions for hypothetical planning exercises, not evidence that the trial used those assumptions or had a particular power. Such illustrations do not turn a single-group observation into a comparative treatment effect. Sample sizes from planning exercises are design quantities, not observed power.

Why can over-dispersion matter?

For count outcomes, over-dispersion means that variation in the observed counts is greater than a statistical model expects. If it is ignored, uncertainty can be understated and inferential results can be too optimistic. This is a general concept. The listed primary endpoint is a participant count rather than a reported event-rate model, and the registry record does not describe an over-dispersion assessment or a model for repeated events. It would not be appropriate to assert that over-dispersion was present or that a particular adjustment was used.

In short, the posted information supports transparent descriptive reading of the recorded participant counts. It does not support reconstruction of unreported tests, confidence intervals, model assumptions, or a full analysis population beyond the endpoint descriptions.

10. Multiplicity, Missing Data and Analysis Populations

The registry record does not report a statistical plan for multiplicity, so it is unclear whether any adjustment across outcomes, time points, grades, or other analyses was planned. The record identifies one primary outcome measure and reports 0 analyses, but that does not establish what analyses may have been conducted outside the registry. Nor does it establish whether other outcomes were designated as secondary or exploratory.

Missing-data methods are not reported in the registry record. The endpoint description says participants receiving any study treatment are evaluable for toxicity, while the primary population is described as all treated and eligible patients. The record does not explain how eligibility, treatment exposure, incomplete follow-up, or unavailable adverse-event information were handled in the posted counts. The timeframe is up to 30 days, but the follow-up completeness for that period is not reported in the registry information.

Analysis populations also require care. The language describing toxicity and the language describing the primary population are similar but not identical. The registry record does not provide participant-level flow or clarify whether every treated participant was eligible for the primary population. No assumptions should be made about exclusions or the number included in any analysis beyond the posted at-risk counts.

These omissions limit reproducibility and interpretation. Without specified multiplicity handling, missing-data methods, and an unambiguous analysis population, readers cannot determine whether the posted counts follow a prespecified analysis plan. The registry record does not report a protocol or statistical analysis plan that resolves these points.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: general disorders and administration site conditions - other, specify (40.0%), social circumstances - other, specify (20.0%).

For the listed arm, the registry records serious adverse events among 3 of 5 participants at risk and other adverse events among 5 of 5 at risk. It also records 3 deaths. These entries describe the safety information posted for this group; they should not be read as a comparison with another treatment. The registry record does not state whether the deaths were considered related to treatment, nor does it report their causes in the information.

The serious-event terms most frequently listed are “General disorders and administration site conditions - Other, specify” at 40.0% and “Social circumstances - Other, specify” at 20.0%. The record does not explain whether these terms overlap within participants or how they relate to the serious-event count. The percentages therefore should not be added together or treated as separate shares of a common total.

Serious adverse events and other adverse events are different reporting categories; the latter should not be assumed to mean mild events. Event seriousness and event severity are not interchangeable concepts. The endpoint description refers to maximum grade under the NCI criteria, but the grade distribution is not reported in the information. These counts identify reported events, not their cause, duration, reversibility, or clinical significance for an individual participant.

12. What the Result Does, and Does Not, Mean

The registry record describes an early-phase, single-group investigation whose stated aims include evaluating the safety of interstitial photodynamic therapy and determining a potentially effective light setting. The posted information gives a limited account of adverse-event counts and lists deaths and serious-event terms. It does not provide a comparative estimate of safety or a reported result establishing a light setting.

The counts should be interpreted as observations in the enrolled group, not as proof that treatment caused each event. Without a concurrent comparator, the record cannot distinguish treatment-related events from events associated with cancer, other care, or chance. The registry does not report attribution for the deaths in the information. Nor does the available summary provide the maximum-grade distribution described in the endpoint definition. Readers therefore cannot infer the full severity pattern from the participant counts alone.

These findings also do not establish whether the intervention is effective. The listed primary endpoint concerns adverse-event frequency, not tumor response or survival. Although the study summary says that a potentially effective light setting is to be evaluated, a result addressing that aim is not reported in the registry record. The title's reference to chemotherapy and the intervention list's mention of nivolumab do not define a usable comparison in the arm information.

The study status is terminated, but the reason is not reported in the registry record. Termination alone does not explain why the study ended or whether it was related to safety, feasibility, funding, enrollment, or another factor. The posted enrollment and safety information should be treated as a description of this study, not a prediction for other patients or a basis for treatment decisions.

13. Why This Trial Matters Statistically

This trial matters statistically because it illustrates the distinction between a safety description and a comparative treatment evaluation. A phase I, single-group study can record adverse events during an early investigation. Its observations may identify issues worth describing, but without a concurrent comparator they do not quantify how event frequency differs under another strategy. That distinction is central when reading counts from a small group.

The record also highlights why endpoints need precise operational definitions. The primary endpoint is described as a participant count based on adverse events, with tabulation by each patient's maximum grade and a timeframe up to 30 days. The posted counts do not include the grade distribution in the information. A clear endpoint definition is valuable, but readers also need the corresponding result detail and a clear account of the population analyzed to assess what was observed.

There is a further interpretive issue in the relationship among the study title, intervention list, and arm description. The title refers to treatment with or without standard-of-care chemotherapy; the intervention list includes nivolumab; and the arm description specifies porfimer sodium and interstitial photodynamic therapy. The registry record does not reconcile these descriptions. That ambiguity makes it difficult to identify the intended contrast or fully understand what treatment exposure the safety counts represent.

Finally, the entry reports 0 analyses and does not report the statistical plan, missing-data methods, or reason for termination. Those gaps do not invalidate the descriptive safety counts, but they limit the conclusions that can be drawn from them. The case underscores the value of complete registry reporting: endpoint details, analysis populations, event attribution, and a transparent account of study conduct help readers distinguish observed data from unanswered questions.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The enrollment is reported as 5, so the safety experience is based on a small group and offers limited precision. The single-group design has no concurrent comparator in the registry description, restricting interpretation to observed events rather than differences between treatment strategies. The record does not report confidence intervals or a formal analysis of the primary outcome.

Several details needed to understand the treatment exposure are unclear. The title refers to porfimer sodium interstitial photodynamic therapy with or without standard-of-care chemotherapy, but the arm description specifies porfimer sodium and the procedure without clarifying a chemotherapy strategy. Nivolumab is listed as an intervention, yet its role in the described arm is not reported. The registry record does not explain the relationship among these entries.

The endpoint definition describes maximum toxicity grade, but the information does not report a grade breakdown. The record also does not report event attribution, causes of death, completeness of follow-up, missing-data handling, or details of the analysis population beyond the stated eligibility descriptions. Serious-event terms are listed with percentages, but the record does not clarify whether these categories can overlap.

The study is marked terminated, and the reason is not reported in the registry record. A sample-size justification, protocol, statistical analysis plan, and interim-analysis information are also not reported. These omissions prevent assessment of prespecification and make it difficult to determine whether posted results reflect all planned analyses. The record's planning assumptions are hypothetical illustrations, not a description of the trial's own design.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer — NCT03727061.
• Registry record last updated 2025-03-11; status last verified 2025-01.
• Results first posted 2025-03-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03727061 is a phase I, single-group study sponsored by Roswell Park Cancer Institute, registered for locally advanced or recurrent head and neck carcinoma. The record reports enrollment of 5, a start date of 2019-07-10, a primary completion date of 2024-10-22, and terminated status. The reason for termination is not reported in the registry record.

The described treatment is porfimer sodium followed by interstitial photodynamic therapy. The primary endpoint is adverse-event frequency under NCI CTCAE version 5.0, up to 30 days. The posted safety information records serious adverse events among 3 of 5 participants at risk, other adverse events among 5 of 5 at risk, and 3 deaths. The record does not provide a comparator, a formal analysis, or the statistical plan. It also does not resolve the roles of chemotherapy and nivolumab mentioned elsewhere in the registration.